Slocum, Gordon & CO LLP Bristol Myers Squibb CO Transaction History

Slocum, Gordon & CO LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 19, 2025	SELL	$44.12 - $59.6 $44,120 - $59,600	-1,000 Reduced 21.52%	3,646 $168,000
Q1 2025 Apr 23, 2025	SELL	$53.9 - $63.11 $11,211 - $13,126	-208 Reduced 4.29%	4,646 $283,000
Q2 2024 Aug 05, 2024	BUY	$40.25 - $52.99 $14,490 - $19,076	360 Added 8.01%	4,854 $201,000
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $38,784 - $46,280	800 Added 21.66%	4,494 $230,000
Q2 2023 Oct 23, 2023	BUY	$63.71 - $70.74 $235,344 - $261,313	3,694 New	3,694 $236,000
Q1 2023 Dec 14, 2023	SELL	$65.71 - $74.53 $12,484 - $14,160	-190 Reduced 5.14%	3,504 $242,000
Q4 2022 Dec 06, 2023	SELL	$68.48 - $81.09 $99,090 - $117,337	-1,447 Reduced 39.17%	2,247 $162 Million

2,672

1.63B

22.4M

25.4M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $92.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Slocum, Gordon & CO LLP, based on Form 13F filings with the SEC.

Stay updated on Slocum, Gordon & CO LLP with notifications on news.